NEJM February 2026 Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents

This clinical study evaluated whether patients with atrial fibrillation who have lived with a drug-eluting stent for at least one year should take a single anticoagulant or a combination of an anticoagulant and an antiplatelet drug. By tracking the occurrence of major health complications and bleeding over a twelve-month period, researchers discovered that those using only a non-vitamin K antagonist oral anticoagulant (NOAC) experienced significantly fewer adverse clinical events. Most notably, the data revealed that monotherapy substantially reduced the risk of bleeding without compromising the patient's cardiovascular safety. Consequently, the trial concludes that for long-term management, a simplified single-drug regimen is not only as effective as dual therapy but may actually provide a superior safety profile for this specific patient group